Further analyses revealed at 31% lower rate of all-cause mortality and a 32% lower rate of cardiovascular mortality at 30 days after randomization in the eplerenone group.
Further analyses revealed at 31% lower rate of all-cause mortality and a 32% lower rate of cardiovascular mortality at 30 days after randomization in the eplerenone group.